Advances in the pharmacotherapy of hereditary angioedema

Research output: Contribution to specialist publicationArticle

Abstract

Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.

Original languageEnglish
PagesHS17-HS21
Volume40
No10
Specialist publicationU.S. Pharmacist
StatePublished - Oct 16 2015

Fingerprint

Complement C1 Inhibitor Protein
Hereditary Angioedemas
Drug therapy
Kinins
Serine Proteinase Inhibitors
Bradykinin
Swelling
Plasmas
Drug Therapy
Inborn Genetic Diseases
Rare Diseases
Pharmacists
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science
  • Pharmacology
  • Pharmacy

Cite this

Advances in the pharmacotherapy of hereditary angioedema. / Cotiguala, Laura M.; Coover, Kelli L.; Bewtra, Againdra K.; Malesker, Mark A.

In: U.S. Pharmacist, Vol. 40, No. 10, 16.10.2015, p. HS17-HS21.

Research output: Contribution to specialist publicationArticle

@misc{797b8431102a42a18fba4421a14523aa,
title = "Advances in the pharmacotherapy of hereditary angioedema",
abstract = "Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.",
author = "Cotiguala, {Laura M.} and Coover, {Kelli L.} and Bewtra, {Againdra K.} and Malesker, {Mark A.}",
year = "2015",
month = "10",
day = "16",
language = "English",
volume = "40",
pages = "HS17--HS21",
journal = "U.S. Pharmacist",
issn = "0148-4818",
publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Advances in the pharmacotherapy of hereditary angioedema

AU - Cotiguala, Laura M.

AU - Coover, Kelli L.

AU - Bewtra, Againdra K.

AU - Malesker, Mark A.

PY - 2015/10/16

Y1 - 2015/10/16

N2 - Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.

AB - Hereditary angioedema (HAE) is a rare genetic disease causing repeated swellings that can be life-threatening. HAE is caused by excessive bradykinin and neurokinin due to a deficient or defective serine protease inhibitor, plasma-derived C1 esterase inhibitor (pdC1-INH). Pharmacotherapy has significantly improved with the development of medications targeting the kinin pathway to prevent and reduce the duration and severity of attacks. Pharmacists’ understanding of these new drugs will ensure that medications are appropriately used and patient outcomes improved.

UR - http://www.scopus.com/inward/record.url?scp=84944453594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944453594&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84944453594

VL - 40

SP - HS17-HS21

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -